Needham analyst Joseph Stringer maintained a Buy rating on Vir Biotechnology (NASDAQ:VIR) on Tuesday, setting a price target of $80, which is approximately 143.24% above the present share price of $32.89.
Stringer expects Vir Biotechnology to post earnings per share (EPS) of $0.85 for the fourth quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Moderate Buy rating of shares in Vir Biotechnology, with an average price target of $63.75.
The analysts price targets range from a high of $80 to a low of $37.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $103.62 million and a net profit of -$53.39 million. The company's market cap is $4.3 billion.
According to TipRanks.com, Needham analyst Joseph Stringer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.6% and a 23.01% success rate.
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.